Skanderborg, Denmark
Skanderborg, Denmark

Time filter

Source Type

HOUSTON, May 10, 2017 /PRNewswire/ -- Laser Prostate Centers of America (LPCA) announces that Francisco Gelpi, M.D., M.P.H. of Houston Metro Urology has joined forces with LPCA to bring comprehensive care to patients suffering from prostate cancer. Dr. Gelpi received his Master's in Public Health from Harvard University in Boston where he also did his fellowship in Urologic Oncology. Prior to this, he completed his internship and residency at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania where he was Chief Urology Resident. Dr. Gelpi is actively involved in numerous organizations in the field including the American Urological Association and his work on new treatment options for prostate cancer has been published in medical journals. Dr. Gelpi's dedication to the field along with his expertise, make him a great asset to the LPCA team. "I am very excited to collaborate with LPCA and further educate patients on prostate cancer treatment while providing the best possible individualized care to each patient," commented Dr. Gelpi. Laser Prostate Centers of America has a multidisciplinary team of urologists and radiologists who evaluate each patient and discuss potential treatment options including focal laser ablation (FLA). The multidisciplinary approach allows patients to fully understand their diagnosis and treatment options to make more educated and informed decisions regarding their care.


DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today initiation of patient dosing in a Phase 2 study of PT2385, the Company’s investigational first-in-class small molecule drug targeting hypoxia-inducible factor 2α (HIF-2α), for patients with von Hippel-Lindau (VHL) disease-associated kidney cancer. The primary objective of the study is to assess the overall response rate (ORR) of VHL disease-associated clear cell renal cell carcinoma (ccRCC) tumors in untreated VHL patients who received PT2385. The study is being conducted in collaboration with the National Cancer Institute (NCI). “There is a significant need for new treatment options for VHL disease, a rare disease with serious and life-long consequences for patients, and for which there are no approved systemic therapies,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “The current standard of care for patients with VHL disease-associated kidney cancer is surgery, which commonly does not result in a cure for these patients.” At the recent ASCO Genitourinary Cancers Symposium, W. Marston Linehan, M.D., Chief of the Urologic Oncology Branch of the NCI, had noted “We are getting ready to start a trial of a drug targeting the HIF-2 pathway with the Peloton PT2385 drug, which we are very encouraged about.” PT2385 is a selective, orally active agent that blocks HIF-2α with potent anti-cancer activity in preclinical models of ccRCC. This open-label Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of PT2385 in patients with VHL disease who have at least one measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally and treatment will be continuous unless there is disease progression. Changes in VHL disease-associated non-ccRCC lesions will also be evaluated. “Patients with VHL disease-associated kidney cancer look forward to having the opportunity to participate in this first-ever study of a drug in patients with VHL disease that targets the immediate downstream effect of the VHL mutation,” said Ilene Sussman of the VHL Alliance, a patient advocacy group for individuals with VHL disease. “If the drug is shown to be effective, it may reduce the number or frequency of surgeries needed. Overall, having an oral medication that could halt or reverse the progression of this disease would greatly benefit patients.” Further information on the clinical trial of PT2385 in VHL disease-associated kidney cancer can be found on www.clinicaltrials.gov (Study identifier: NCT03108066). Von Hippel-Lindau disease is a hereditary cancer syndrome caused by a germline mutation in or deletion of the VHL gene, and patients are at risk for developing tumors and fluid-filled sacs (cysts) in a number of organs. Renal cell carcinoma occurs in about 70 percent of individuals with VHL disease and is the leading cause of mortality. Approximately 6,000 people have VHL disease in the U.S. Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops novel small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics’ lead programs are small molecule inhibitors targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers. To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.


News Article | May 15, 2017
Site: www.eurekalert.org

PORTLAND, OR - It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true and now a major U.S. study has done the same. Dr. Edward Messing, an investigator with SWOG, the international clinical trials network funded by the National Cancer Institute, has found that an immediate infusion of the common chemotherapy agent gemcitabine after the removal of a bladder cancer tumor will significantly reduce the risk of cancer recurrence. The Winfield W. Scott Professor and Chairman of Urology at the University of Rochester, Messing will present results of this Phase III, blinded clinical trial during a May 15 oral presentation at the annual meeting of the American Urological Association (AUA) held May 12-16 in Boston. "This one extra step, using a drug that's fairly inexpensive, has impressive results," Messing said. "Urologists in Europe and Canada have been doing this procedure for more than 20 years with other chemotherapy drugs, with the research to prove it. Even the AUA recommends it. Now that we've got results from an American study, using a readily available drug that is very well-tolerated, maybe American urologists will start using gemcitabine this way. I certainly hope this finally changes our standard of care." Messing is former president of the Society of Urologic Oncology and, in 2013, was awarded the prestigious Presidential Citation from the AUA for his work as a bladder cancer researcher and educator. Messing led a SWOG team that conducted the trial, S0337, which enrolled 406 eligible patients with non-muscle invading bladder cancer. Bladder cancer is the sixth most commonly diagnosed cancer in the United States, and the third most common among men. The low grade, non-muscle invasive form of the disease is common, making up about half of all newly diagnosed cases. Treatment includes a procedure called transurethral resection for bladder tumor, or TURBT, which involves a surgeon removing cancerous tissue from the bladder. In the Messing study, patients were randomized into two groups. One group, after TURBT, received a single 3.5-ounce instillation of gemcitabine, which was administered directly after surgery and allowed to sit in the bladder for one hour. The drug kills cancer cells, and is often used to treat advanced bladder cancer in combination with the chemotherapy drug cisplatin. The other group of patients, after TURBT, received an infusion of saline only. Both groups were followed for four years. Results were strong and clear: There was a significant 34 percent reduction in risk of recurrence for patients receiving the gemcitabine infusion. While more of those patients experienced moderate post-surgical pain, investigators found, they experienced no other additional side effects, such as bleeding, compared with the patients who received a saline infusion alone. "The big deal here is that cancer recurrence is common for people diagnosed with this less aggressive form of bladder cancer," Messing said. "I know some patients who undergo four TURBT procedures a year. If we can cut down on these recurrences, we will save a lot of people a lot of pain, money, and time lost to recovery." Messing said after his AUA presentation, he will submit his findings to a peer-reviewed journal for publication. Messing's SWOG study team includes: Cathy Tangen, DrPH, of Fred Hutchinson Cancer Research Center; Deepak Sahasrabudhe, MD, of University of Rochester; Theresa Koppie of Oregon Health & Science University; David Wood Jr., MD, of Beaumont Health; Philip Mack, PhD, of UC Davis Cancer Center; Robert Svatek, MD, of UT Health San Antonio; Christopher Evans, MD, UC Davis Cancer Center; Khaled Hafez, MD, of University of Michigan; Daniel Culkin, MD, of University of Oklahoma; Timothy Brand, MD, of Madigan Army Medical Center; Lawrence Karsh, MD, of The Urology Center of Colorado; Jeffrey Holzbeierlein, MD, of University of Kansas Cancer Center; Shandra Wilson, MD, of University of Colorado; Guanming Wu, PhD, of Oregon Health & Science University; Melissa Plets, MS, Fred Hutchinson Cancer Research Center; Seth Lerner, MD, Baylor College of Medicine; Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada; and Ian Thompson, Jr., MD, of CHRISTUS Santa Rosa Medical Center. Research reported in this presentation was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers CA180888 and CA180819. Eli Lilly and Company also supported the work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Eli Lilly and Company. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct cancer clinical trials. Founded in 1956, SWOG's 1,300 treatment and prevention trials have led to the approval of 14 cancer drugs, changed the standard of cancer care more than 100 times, and saved more than 2 million years of human life. SWOG is funded by the National Cancer Institute and is a proud member of the NCI's National Clinical Trials Network and the NCI Community Oncology Research Program. Learn more at swog.org.


News Article | May 25, 2017
Site: www.prnewswire.com

Currently a practitioner at Houston Methodist, Dr. Woods was formerly in solo private practice for 16 years. Prior to that she served as full-time faculty at Baylor College of Medicine and Director of Therapeutic Endoscopy at Ben Taub Hospital, both in the Houston area. During her 10 years as faculty, she trained many fellows in the art of endoscopy. She received the ASGE Endoscopic Research Award in 1991, and the ASGE Distinguished Service Award in 2015. She was selected to serve on the U.S. Food and Drug Administration Gastrointestinal and Urologic Devices Panel in 1993. Since then, she has served continuously in various capacities for the panel. Throughout her multiple practices as academician, private practitioner and employed physician, Dr. Woods has maintained a passion for national service, with a focus on bringing the voice of the practicing clinician to the Society. As ASGE President, she will host the 2017 EndoVators Summit on the topic of "Simulators and the Future of Endoscopic Training," to explore current training models and methods of assessing endoscopic competence, identify the inherent deficiencies in the current model and define skills that would benefit from simulation training for new trainees and practitioners wishing to learn a new skill.  Additionally, she will focus on advocacy in areas of practice management and reimbursement that will benefit both patients and providers. Dr. Woods shares with her fellow GI endoscopists a love of the technology that allows them not only to identify disease but also to use the scope as a tool for treatment and healing. Above all, she is passionate about developing relationships with patients and teaching them about disease management. She received her medical degree from the University of Missouri-Kansas City in 1983. Her internship and residency were in Internal Medicine at Baylor College of Medicine, Houston, Texas. She was Chief Medical Resident at the Houston VA Medical Center and then went on to a Gastroenterology fellowship at University of Texas Southwestern in Dallas, Texas. She returned to Baylor College of Medicine in Houston for an Advanced Endoscopy Fellowship and then joined the Baylor faculty. Her primary clinical areas of interest are general gastroenterology with a focus on EMR (endoscopic mucosal resection) of esophageal and colonic lesions, advanced polypectomy and ablation of Barrett's esophagus. Dr. Woods has authored or co-authored numerous publications and has been an invited speaker at many local and national conferences. She has been consistently named as a Best Doctor in various national and local publications. About the American Society for Gastrointestinal Endoscopy Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with more than 15,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area. About Endoscopy Endoscopy is performed by specially-trained physicians called endoscopists using the most current technology to diagnose and treat diseases of the gastrointestinal tract. Using flexible, thin tubes called endoscopes, endoscopists can access the human digestive tract without incisions via natural orifices. Endoscopes are designed with high-intensity lighting and fitted with precision devices that allow viewing and treatment of the gastrointestinal system. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leading-gastrointestinal-society-names-karen-l-woods-md-to-president-300464130.html


Neckers L.,Urologic | Workman P.,Institute of Cancer Research
Clinical Cancer Research | Year: 2012

Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70. ©2012 AACR.


Flessner M.F.,Urologic
Clinical Journal of the American Society of Nephrology | Year: 2014

The National Institute of Diabetes and Digestive and Kidney Diseases–supported Kidney Research National Dialogue asked the scientific community to formulate and prioritize research objectives aimed at improved understanding of kidney function and disease progression. Over the past 2 years, 1600 participants posted almost 300 ideas covering all areas of kidney disease. An overriding theme that evolved through these discussions is the need to move beyond pathology to take advantage of basic science and clinical research opportunities to improve diagnostic classification and therapeutic options for people with primary glomerular disease. High-priority research areas included focus on therapeutic targets in glomerular endothelium and podocytes, regenerating podocytes through developmental pathways, use of longitudinal phenotypically defined disease cohorts to improve classification schemes, identifying biomarkers, disease-specific therapeutics, autoantibody triggers, and changing the clinical research culture to promote participation in clinical trials. Together, these objectives provide a path forward for improving clinical outcomes of glomerular disease. © 2014 by the American Society of Nephrology


Kidney cancer is not a single disease; it is made up of a number of different types of cancer, including clear cell, type 1 papillary, type 2 papillary, chromophobe, TFE3, TFEB, and oncocytoma. Sporadic, nonfamilial kidney cancer includes clear cell kidney cancer (75%), type 1 papillary kidney cancer (10%), papillary type 2 kidney cancer (including collecting duct and medullary RCC) (5%), the microphalmia-associated transcription (MiT) family translocation kidney cancers (TFE3, TFEB, and MITF), chromophobe kidney cancer (5%), and oncocytoma (5%). Each has a distinct histology, a different clinical course, responds differently to therapy, and is caused by mutation in a different gene. Genomic studies identifying the genes for kidney cancer, including the VHL, MET, FLCN, fumarate hydratase, succinate dehydrogenase, TSC1, TSC2, and TFE3 genes, have significantly altered the ways in which patients with kidney cancer are managed. While seven FDA-approved agents that target the VHL pathway have been approved for the treatment of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and gene copy number, will be required to gain a complete understanding of the genetic basis of kidney cancer and of the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with this disease. © 2012, Published by Cold Spring Harbor Laboratory Press.


Finley D.S.,Urologic
The oncologist | Year: 2011

In the past 15 years, there has been an increased understanding of the tumor biology of renal cell carcinoma (RCC). The identification of vascular endothelial growth factor (VEGF), its related receptor (VEGFR), and the mammalian target of rapamycin as dysregulated signaling pathways in the development and progression of RCC has resulted in the rational development of pharmaceutical agents capable of specifically targeting key steps in these pathways. Clinical trials have demonstrated survival benefit with these agents, particularly in clear cell RCC patients. However, metastatic RCC will progress in all patients, resulting in a critical need to determine patient risk and optimize treatment. The goal of this article is to highlight the significant breakthroughs made in understanding the critical genetic alterations and signaling pathways underlying the pathogenesis of RCC. The discovery of prognostic factors and development of comprehensive nomograms to stratify patient risk and predictive biomarkers to facilitate individualized treatment selection and predict patient response to therapy also are reviewed.


TMPRSS2:ERG gene fusions, the most common molecular subtype of ETS family gene fusions occur in ∼50% of prostate carcinomas (PCas) and ∼20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions. ERG gene fusions have not yet been demonstrated in isolated benign prostate tissue, isolated high-grade prostatic intraepithelial neoplasia, or benign cancer mimics. Taken together, ERG gene fusions are the most prostate cancer-specific biomarker yet identified and define a specific molecular subtype of PCa with important clinical and biological implications. ERG gene fusions result in the overexpression of a chimeric fusion transcript that encodes a truncated ERG protein product. Recently, N-terminal epitope-targeted mouse (9FY) and C-terminal-targeted rabbit monoclonal (EPR 3864) ERG antibodies are commercially available and are increasingly utilized as a surrogate for TMPRSS2:ERG gene fusions. Until recently, because of lack of availability of reliable ERG antibody, the most commonly utilized methods for studying ERG aberrations in PCa specimens included fluorescence in situ hybridization or reverse transcriptase polymerase chain reaction. The knowledge gleaned from these studies has significantly improved our understanding of molecular biology of ERG gene fusions. With availability of highly specific anti-ERG monoclonal antibodies, there are now unprecedented opportunities to explore and validate clinical applications of ERG antibody in routine pathology practice, which has just started. This review provides a brief background of molecular biology of ERG gene fusions in PCa and focuses on characterizing the current state of ERG oncoprotein and determining the role of ERG immunohistochemistry in the diagnosis and biological stratification of prostate cancer. Copyright © 2013 by Lippincott Williams & Wilkins.


Patent
Urologic | Date: 2015-11-12

Device and method for correcting urinary incontinence and urinary retention, by implanting a urinary flow control device for elective user control of urinary function in male and female patients. The device is a mechanical valve to a natural or artificial bladder, and includes a to reach the abdominal wall of the patient. Preferably a bladder anti-prolapse skirt is attached between the bladder and control valve. The device provides a urine flow channel that passes through the valve from one side to the other of a valve seat where an actuator with a mating stopper is controlled to open and close the valve at the election of the user with an external controller. The valve is an occlusion type (seat with stopper), or a pinch type. The flow channel may be an artificial urethra passing through a pinch valve.

Loading Urologic collaborators
Loading Urologic collaborators